Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T09977 Target Info
Target Name Leucine-rich repeat kinase 2 S935 phosphorylation (LRRK2 pS935)
Synonyms PARK8 S935 phosphorylation; LRRK2 S935 phosphorylation; Dardarin S935 phosphorylation
Target Type Patented-recorded Target
Gene Name LRRK2
Biochemical Class Kinase
UniProt ID
LRRK2_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2014137728
Title Compounds Inhibiting Leucine-Rich Repeat Kinase Enzyme Activity.
Abstract The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Applicant(s) Merck Sharp & Dohme Corp
Representative Drug(s) D0FS9X Drug Info IC50 = 1.4 nM [1]
Patent ID WO2014137725
Title Compounds Inhibiting Leucine-Rich Repeat Kinase Enzyme Activity.
Abstract The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.
Applicant(s) Merck Sharp & Dohme Corp
Representative Drug(s) D0FS9X Drug Info IC50 = 1.4 nM [1]
Patent ID WO2014137723
Title Compounds Inhibiting Leucine-Rich Repeat Kinase Enzyme Activity.
Abstract The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Applicant(s) Merck Sharp & Dohme Corp
Representative Drug(s) D0FS9X Drug Info IC50 = 1.4 nM [1]
Patent ID WO2014137719
Title Compounds Inhibiting Leucine-Rich Repeat Kinase Enzyme Activity.
Abstract The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Applicant(s) Merck Sharp & Dohme Corp
Representative Drug(s) D0FS9X Drug Info IC50 = 1.4 nM [1]
Patent ID WO2014134776
Title Compounds Inhibiting Leucine-Rich Repeat Kinase Enzyme Activity.
Abstract The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.
Applicant(s) Merck Sharp & Dohme Corp
Representative Drug(s) D0FS9X Drug Info IC50 = 1.4 nM [1]
Patent ID WO2014134774
Title Compounds Inhibiting Leucine-Rich Repeat Kinase Enzyme Activity.
Abstract Disclosed are indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which LRRK2 kinase is involved. Also disclosed are pharmaceutical compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.
Applicant(s) Merck Sharp & Dohme Corp
Representative Drug(s) D0FS9X Drug Info IC50 = 1.4 nM [1]
References  Top
REF 1 Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.